trichostatin A
Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.
Cross Reference
Introduction
To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with trichostatin A?
trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with trichostatin A
PubChem Associated disorders and diseases
What pathways are associated with trichostatin A
Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with trichostatin A?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with trichostatin A?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with trichostatin A?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with trichostatin A?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with trichostatin A?
Mouse Model
Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).
Xenograft Model
Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).
Cancer Model
Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with trichostatin A
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Samiec M et al. | Trichostatin A-mediated epigenetic transformation of adult bone marrow-derived mesenchymal stem cells biases the in vitro developmental capability, quality, and pluripotency extent of porcine cloned embryos. | 2015 | Biomed Res Int | pmid:25866813 |
| Hou H et al. | Influence of intra-articular administration of trichostatin a on autologous osteochondral transplantation in a rabbit model. | 2015 | Biomed Res Int | pmid:25866784 |
| Chan ST et al. | Oral and intraperitoneal administration of quercetin decreased lymphocyte DNA damage and plasma lipid peroxidation induced by TSA in vivo. | 2014 | Biomed Res Int | pmid:24868531 |
| Florea AM | DNA methylation pyrosequencing assay is applicable for the assessment of epigenetic active environmental or clinical relevant chemicals. | 2013 | Biomed Res Int | pmid:24093099 |
| Ilicic M et al. | Modulation of Progesterone Receptor Isoform Expression in Pregnant Human Myometrium. | 2017 | Biomed Res Int | pmid:28540297 |
| Piotrowska H and Jagodzinski PP | Trichostatin A, sodium butyrate, and 5-aza-2'-deoxycytidine alter the expression of glucocorticoid receptor alpha and beta isoforms in Hut-78 T- and Raji B-lymphoma cell lines. | 2007 | Biomed. Pharmacother. | pmid:17498915 |
| Drzewiecka H and Jagodzinski PP | Trichostatin A reduced phospholipase C gamma-1 transcript and protein contents in MCF-7 breast cancer cells. | 2012 | Biomed. Pharmacother. | pmid:22257695 |
| Cheng SP et al. | Regulation of leptin receptor expression in human papillary thyroid cancer cells. | 2012 | Biomed. Pharmacother. | pmid:22560341 |
| Åuczak MW and JagodziÅ„ski PP | Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells. | 2009 | Biomed. Pharmacother. | pmid:18602794 |
| Feng W et al. | Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. | 2015 | Biomed. Pharmacother. | pmid:26349994 |
| Sobolewski C et al. | Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells. | 2015 | Biomolecules | pmid:26343742 |
| McCulloch MW et al. | Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. | 2009 | Bioorg. Med. Chem. | pmid:19022675 |
| Fu J et al. | Discovery of 1H-benzo[d][1,2,3]triazol-1-yl 3,4,5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase. | 2010 | Bioorg. Med. Chem. | pmid:21067930 |
| Saha A et al. | Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity. | 2013 | Bioorg. Med. Chem. | pmid:23719282 |
| Schäfer S et al. | Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). | 2008 | Bioorg. Med. Chem. | pmid:18054239 |
| Terracciano S et al. | Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222. | 2010 | Bioorg. Med. Chem. | pmid:20381359 |
| Chen PC et al. | Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. | 2008 | Bioorg. Med. Chem. | pmid:18397827 |
| Whitehead L et al. | Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. | 2011 | Bioorg. Med. Chem. | pmid:21723733 |
| Feng T et al. | Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). | 2013 | Bioorg. Med. Chem. | pmid:23820574 |
| Mukherjee P et al. | Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. | 2008 | Bioorg. Med. Chem. | pmid:18362073 |
| Di Micco S et al. | Structural basis for the design and synthesis of selective HDAC inhibitors. | 2013 | Bioorg. Med. Chem. | pmid:23693069 |
| Patil V et al. | Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. | 2010 | Bioorg. Med. Chem. | pmid:19914074 |
| Nishino N et al. | Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides. | 2008 | Bioorg. Med. Chem. | pmid:17900911 |
| Shivashimpi GM et al. | Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. | 2007 | Bioorg. Med. Chem. | pmid:17881232 |
| Estiu G et al. | On the inhibition of histone deacetylase 8. | 2010 | Bioorg. Med. Chem. | pmid:20472442 |
| Kaldre D et al. | Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids. | 2015 | Bioorg. Med. Chem. | pmid:26048026 |
| Kiyokawa S et al. | New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group. | 2010 | Bioorg. Med. Chem. | pmid:20452226 |
| Nishino N et al. | Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. | 2004 | Bioorg. Med. Chem. Lett. | pmid:15109626 |
| Marson CM et al. | Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. | 2004 | Bioorg. Med. Chem. Lett. | pmid:15109636 |
| Vaisburg A et al. | (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. | 2004 | Bioorg. Med. Chem. Lett. | pmid:14684344 |
| Hoque MA et al. | Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases. | 2012 | Bioorg. Med. Chem. Lett. | pmid:23021104 |
| Krennhrubec K et al. | Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17346959 |
| Rajak H et al. | 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21875796 |
| Vaidya AS et al. | Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose. | 2012 | Bioorg. Med. Chem. Lett. | pmid:23010266 |
| Jose B et al. | Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. | 2004 | Bioorg. Med. Chem. Lett. | pmid:15454224 |
| Liao V et al. | Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. | 2012 | Bioorg. Med. Chem. Lett. | pmid:22932316 |
| Smil DV et al. | Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. | 2009 | Bioorg. Med. Chem. Lett. | pmid:19111466 |
| Islam NM et al. | Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length. | 2010 | Bioorg. Med. Chem. Lett. | pmid:20045316 |
| Riester D et al. | Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases. | 2009 | Bioorg. Med. Chem. Lett. | pmid:19457659 |
| Uesato S et al. | Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. | 2002 | Bioorg. Med. Chem. Lett. | pmid:11992774 |
| Hooven LA et al. | Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. | 2005 | Bioorg. Med. Chem. Lett. | pmid:15713371 |
| Chen B et al. | Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. | 2005 | Bioorg. Med. Chem. Lett. | pmid:15713393 |
| Yu D et al. | Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21840716 |
| Vasudevan A et al. | Heterocyclic ketones as inhibitors of histone deacetylase. | 2003 | Bioorg. Med. Chem. Lett. | pmid:14592473 |
| Choi E et al. | Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21256006 |
| Nakao Y et al. | Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. | 2008 | Bioorg. Med. Chem. Lett. | pmid:18397826 |
| Mazitschek R et al. | Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. | 2008 | Bioorg. Med. Chem. Lett. | pmid:18430569 |
| Charrier C et al. | Synthesis of rigid trichostatin A analogs as HDAC inhibitors. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16904890 |
| Charrier C et al. | Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17897824 |
| Lavoie R et al. | Design and synthesis of a novel class of histone deacetylase inhibitors. | 2001 | Bioorg. Med. Chem. Lett. | pmid:11597413 |